Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
How do you manage a cytology-negative pleural effusion that develops after lung RT?
Related Questions
How do you construct your target volumes for superior sulcus tumors?
Would a metal endobronchial stent within the treatment field change your radiation treatment plan for a thoracic malignancy?
How would you post-operatively manage a peripheral stage I small cell lung carcinoma s/p upfront wedge resection with an R1 microscopic positive margin along the staple line and visceral pleural invasion?
Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?
What clinical and pathologic features do you use to discern whether >= 2 synchronous lung nodules, biopsy proven lung adenocarcinoma, are different primaries versus metastatic disease?
Is there a chest wall constraint you typically use for 60 Gy in 15 fraction NSCLC treatment?
How do you treat Stage IIIC T4N3 NSCLC?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?
What is your planning approach for SBRT when the tumor abuts the great vessels such as aortic arch or SVC?
